Huang Xiaochun, CEO of British GDK Medical Group, and his party visited the platform for exchange and discussion.

On the afternoon of October 17th, Huang Xiaochun, CEO of British GDK Medical Group, and COO Hong Xiuhui and his party visited the platform to further implement the exchange results of life science and medical service counselor An Ruihui from the Commercial and Trade Department of British Embassy in China and continuously deepen the innovative cooperation between Henan and Britain in the field of life science. Ren Xiang, founder of the platform, Geng Hui, vice chairman, Wei Dan, CEO of China-UK Biomedical Innovation Sharing Accelerator, Damon, international project director, and other relevant industry and department heads warmly received and participated in the forum.

Huang Xiaochun introduced the British GDK Medical Group in detail. She said that the British GDK Medical Group works closely with the medical schools of Oxford University, Cambridge University, Imperial College of Technology and King's University and their affiliated hospitals, and is committed to the discipline construction between Chinese and British medical institutions. Huang Xiaochun also introduced international cooperation hospitals, professional personnel training, joint training bases and other projects to the platform, hoping to establish a long-term cooperative relationship with the platform and jointly promote the high-quality development of the life science industry in China and Britain.

Based on the actual development of Henan local life science field, Dr. Wei Dan analyzed the recommended projects and introduced the related cooperation direction and resources to GDK Medical Group in the UK. He suggested that the two sides can establish a public service platform around the field of life sciences in China and Britain to provide international and one-stop innovative services for related enterprises in the two places.

Subsequently, the two sides conducted in-depth exchanges on key issues such as talent introduction, achievement transfer and project landing, and initially reached a consensus on cooperation. After that, the two sides will jointly build a collaborative innovation platform, collaborate with all social factors, and pool international medical resources to form a big brand system, which will empower and enhance the innovation and development of life sciences in China and Britain.